Phlox Therapeutics uses smart RNA designs to target multiple Lamin A/C mutations, offering therapies for rare genetic cardiomyopathies. Their constructs, developed by the group of Amsterdam UMC Professor Yigal Pinto, show promising therapeutic effects in patient-derived cardiomyocytes. Phlox Therapeutics aims to expand their technology to other treatment-resistant cardiomyopathies.
